BR112015022617A2 - polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável - Google Patents

polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável

Info

Publication number
BR112015022617A2
BR112015022617A2 BR112015022617A BR112015022617A BR112015022617A2 BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2 BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2
Authority
BR
Brazil
Prior art keywords
thermostable
recombinant polypeptide
expression vector
immunogenic composition
polypeptide
Prior art date
Application number
BR112015022617A
Other languages
English (en)
Portuguese (pt)
Inventor
Jan Haijema Bert
Alexander Maria De Haan Cornelis
Josephus Marie Rottier Petrus
Original Assignee
Mucosis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucosis Bv filed Critical Mucosis Bv
Publication of BR112015022617A2 publication Critical patent/BR112015022617A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015022617A 2013-03-14 2014-03-12 polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável BR112015022617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/828,667 US9060975B2 (en) 2013-03-14 2013-03-14 Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
PCT/EP2014/054804 WO2014140083A1 (en) 2013-03-14 2014-03-12 Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions

Publications (1)

Publication Number Publication Date
BR112015022617A2 true BR112015022617A2 (pt) 2017-10-31

Family

ID=50241453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022617A BR112015022617A2 (pt) 2013-03-14 2014-03-12 polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável

Country Status (8)

Country Link
US (2) US9060975B2 (enExample)
EP (2) EP3178840A1 (enExample)
JP (1) JP6285469B2 (enExample)
CN (2) CN107029227A (enExample)
AU (1) AU2014230822B2 (enExample)
BR (1) BR112015022617A2 (enExample)
CA (1) CA2905571A1 (enExample)
WO (1) WO2014140083A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000145T1 (it) 2013-02-01 2020-05-08 Medimmune Llc Epitopi di proteina f di virus sinciziale respiratorio
WO2014152534A1 (en) 2013-03-14 2014-09-25 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
KR20180085730A (ko) * 2015-10-29 2018-07-27 에모리 유니버시티 키메라 rsv, 면역원성 조성물, 및 사용 방법
CN116063551A (zh) * 2016-04-05 2023-05-05 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f蛋白
BR112018074483A2 (pt) * 2016-05-30 2019-03-19 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
CN113832116B (zh) * 2017-01-12 2024-09-13 厦门大学 稳定呼吸道合胞病毒融合蛋白的方法
PL3601367T3 (pl) 2017-03-30 2025-03-31 The University Of Queensland Cząsteczki chimeryczne i ich zastosowania
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
CN109694400A (zh) * 2019-01-31 2019-04-30 苏州高泓利康生物科技有限公司 一种表达呼吸道合胞病毒f蛋白及其制备方法
CN114269373A (zh) 2019-04-02 2022-04-01 赛诺菲 抗原性多聚呼吸道合胞病毒多肽
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
US20220306697A1 (en) 2019-09-04 2022-09-29 University Of Washington Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
CN115715326A (zh) * 2020-04-22 2023-02-24 浦项工科大学校产学协力团 可形成三聚体的源自于流感病毒表面蛋白的重组血球凝集素蛋白及其用途
CA3179246A1 (en) * 2020-05-19 2021-11-25 Yves Durocher Use of resistin as a trimerization partner for expression of trimeric proteins
CN112480217B (zh) * 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
KR20250140099A (ko) * 2023-02-03 2025-09-24 노바백스, 인코포레이티드 Rsv f 백신 제형
WO2024192698A1 (zh) * 2023-03-22 2024-09-26 中科牧维(南京)生物科技有限公司 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂
WO2024251281A1 (zh) * 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
CN117886902B (zh) * 2023-12-21 2024-11-26 易康生物(苏州)有限公司 改良的呼吸道合胞病毒融合f蛋白突变体及其应用
US12383614B2 (en) 2023-12-21 2025-08-12 Yikang Biotech (Suzhou) Co., Ltd. Mutants of respiratory syncytial virus fusion proteins
CN120329390A (zh) * 2025-03-03 2025-07-18 中国医学科学院医学生物学研究所 基于异源三聚体基序的蛋白的改造及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916726A1 (en) 1997-11-13 1999-05-19 Rijksuniversiteit te Groningen Attaching substances to micro-organisms
CN100513548C (zh) 2001-06-11 2009-07-15 应用超微系统股份有限公司 将AcmA型蛋白质锚融合体与微生物细胞壁材料进行结合的改良方法
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2010149743A2 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
ES2583257T3 (es) 2009-06-24 2016-09-20 Glaxosmithkline Biologicals S.A. Antígenos recombinantes del VSR
ES2563730T3 (es) * 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
BR112013024157A2 (pt) 2011-03-22 2016-12-06 Mucosis Bv composições imunogênicas em forma particulada e métodos para produção destas
SI2707385T1 (en) 2011-05-13 2018-01-31 Glaxosmithkline Biologicals Sa Pregnant RSV F antigens

Also Published As

Publication number Publication date
CN107029227A (zh) 2017-08-11
US9060975B2 (en) 2015-06-23
JP2016510983A (ja) 2016-04-14
EP2970393B1 (en) 2017-01-11
US20140271696A1 (en) 2014-09-18
CN105246910A (zh) 2016-01-13
JP6285469B2 (ja) 2018-02-28
AU2014230822B2 (en) 2018-04-12
WO2014140083A1 (en) 2014-09-18
EP2970393A1 (en) 2016-01-20
USRE47471E1 (en) 2019-07-02
CA2905571A1 (en) 2014-09-18
AU2014230822A1 (en) 2015-10-01
EP3178840A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
BR112015022617A2 (pt) polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
CL2021001750A1 (es) Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020)
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
WO2020063370A3 (zh) 免疫组合物及其制备方法与应用
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
MX384992B (es) Combinaciones inmunógenas.
TR201903074T4 (tr) Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler.
MX2015013065A (es) Proteinas f de rsv de prefusion y su uso.
MX2018003298A (es) Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
EA201892735A1 (ru) Состав вакцины против hiv
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
EA202191622A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
EA202092521A1 (ru) Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
MX389111B (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
EA201691611A1 (ru) Конструкции белка uspa2 и их применения
NZ749058A (en) Preparation of 212pb labeled monoclonal antibodies
MX387396B (es) Un poliepitope quimerico de virus de dengue compuesto por fragmentos de proteinas no estructurales y su uso en una composicion inmunogenica contra infeccion de virus de dengue.
BR112013000345A2 (pt) composições antigênicas para vírus sincicial respiratório e métodos
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
MX2019006105A (es) Conjugados de vmen-antigeno y uso de los mismos.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 2020-01-07